Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cellular and Molecular Biology 73: Translational Genomics

Targeted approaches to the treatment of ovarian cancer.

Holly K. Dressman, Johnathan M. Lancaster, Gina Chan, Janiel M. Cragun, Andrea Bild, Robyn Sayer, Jennifer Clarke, Jeffrey Marks, Anil Potti, Joseph R. Nevins and Andrew Berchuck
Holly K. Dressman
Duke University Medical Center, Durham, NC, H. Lee Moffitt Cancer Center, Tampa, FL, Duke University, Durham, NC, Duke University Medical Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johnathan M. Lancaster
Duke University Medical Center, Durham, NC, H. Lee Moffitt Cancer Center, Tampa, FL, Duke University, Durham, NC, Duke University Medical Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gina Chan
Duke University Medical Center, Durham, NC, H. Lee Moffitt Cancer Center, Tampa, FL, Duke University, Durham, NC, Duke University Medical Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janiel M. Cragun
Duke University Medical Center, Durham, NC, H. Lee Moffitt Cancer Center, Tampa, FL, Duke University, Durham, NC, Duke University Medical Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Bild
Duke University Medical Center, Durham, NC, H. Lee Moffitt Cancer Center, Tampa, FL, Duke University, Durham, NC, Duke University Medical Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robyn Sayer
Duke University Medical Center, Durham, NC, H. Lee Moffitt Cancer Center, Tampa, FL, Duke University, Durham, NC, Duke University Medical Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Clarke
Duke University Medical Center, Durham, NC, H. Lee Moffitt Cancer Center, Tampa, FL, Duke University, Durham, NC, Duke University Medical Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Marks
Duke University Medical Center, Durham, NC, H. Lee Moffitt Cancer Center, Tampa, FL, Duke University, Durham, NC, Duke University Medical Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anil Potti
Duke University Medical Center, Durham, NC, H. Lee Moffitt Cancer Center, Tampa, FL, Duke University, Durham, NC, Duke University Medical Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph R. Nevins
Duke University Medical Center, Durham, NC, H. Lee Moffitt Cancer Center, Tampa, FL, Duke University, Durham, NC, Duke University Medical Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Berchuck
Duke University Medical Center, Durham, NC, H. Lee Moffitt Cancer Center, Tampa, FL, Duke University, Durham, NC, Duke University Medical Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2006
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 47, 2006

Abstract

5694

Background: The majority of patients with advanced stage epithelial ovarian cancer will develop platinum-resistant recurrent disease requiring salvage therapy. Response rates in this setting are generally less than 20%, with the potential for significant cumulative toxicities. Currently, our ability to tailor therapy to patients most likely to respond to individual salvage agents is limited by an incomplete understanding of the biology that underlies chemo-responsiveness. Objectives: To characterize the molecular genetic basis of advanced epithelial ovarian cancer response to topotecan salvage chemotherapy and identify opportunities for novel therapeutic additions to the standard treatment strategy based on genomic data. Methods: Ovarian cancers were obtained at the time of primary surgery and assayed for gene expression in 48 patients who went on to develop persistent or recurrent disease when treated with topotecan salvage therapy. A gene expression based model was developed to predict response to topotecan salvage therapy. In parallel, we further evaluated the role of a series of gene expression signatures of activated oncogenic signaling pathways as indicators of therapeutic opportunities, combined with a prediction of topotecan response, in 48 ovarian cancers, 14 ovarian cancer cell lines and 54 other human cancer cell lines. Results: We have demonstrated the ability to identify ovarian cancer patients unlikely to have a clinical response to topotecan salvage chemotherapy with an overall accuracy of 81% for correctly predicting response to topotecan (80% responders and 83% non-responders) in a leave-one-out cross validation. We also show that the prediction of pathway deregulation in cancer cell lines predicts sensitivity to therapeutic agents that target components of two pathways, src and beta-catenin. We have further investigated the extent to which the effect of combined therapies is additive in relation to pathway status. Specifically, a collection of ovarian cancer cell lines were assayed for sensitivity to topotecan either with or without a src inhibitor (SU6656). The addition of a src inhibitor (SU6656) increased ovarian cancer cell line sensitivity to topotecan. Conclusions: Our data suggest that we can use gene expression profiles from primary ovarian cancers obtained at the time of initial surgical cytoreduction to not only predict response to topotecan, but also to identify alternate therapeutic options for patients predicted to be both topotecan-resistant as well as topotecan-sensitive. Deregulation of the src and beta-catenin oncogenic signaling pathways appears to be associated with relative topotecan resistance in human ovarian cancers and cancer cell lines. This relative resistance to topotecan can be partially reversed in-vitro using a src inhibitor. Our analysis suggests that the src and beta-catenin oncogenic signaling pathways may be important in topotecan responsiveness in many other human cancers.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 66 (8 Supplement)
April 2006
Volume 66, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Targeted approaches to the treatment of ovarian cancer.
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Targeted approaches to the treatment of ovarian cancer.
Holly K. Dressman, Johnathan M. Lancaster, Gina Chan, Janiel M. Cragun, Andrea Bild, Robyn Sayer, Jennifer Clarke, Jeffrey Marks, Anil Potti, Joseph R. Nevins and Andrew Berchuck
Cancer Res April 15 2006 (66) (8 Supplement) 1339;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Targeted approaches to the treatment of ovarian cancer.
Holly K. Dressman, Johnathan M. Lancaster, Gina Chan, Janiel M. Cragun, Andrea Bild, Robyn Sayer, Jennifer Clarke, Jeffrey Marks, Anil Potti, Joseph R. Nevins and Andrew Berchuck
Cancer Res April 15 2006 (66) (8 Supplement) 1339;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Distinct patterns of 1p deletions in oligodendroglial and astrocytic tumors analyzed by a chromosome 1 tile path array-CGH.
  • DNA sequence analysis of known cancer genes in the NCI-60 cell lines.
  • Somatic sequence alterations in genes selected by expression profile analysis of breast carcinomas.
Show more Cellular and Molecular Biology 73: Translational Genomics
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement